Paige Jarreau

Translating Genetic Findings Into Dementia Treatments

Tracing the Path From Bench to Bedside

Tuesday, December 17, 2024

When IRP graduate student Pilar Alvarez Jerez looked at the results of a recent experiment, she noticed that when a particular genetic variant is present in a gene called GBA1, it causes a change in the gene's activity. The GBA1 variant, which is associated with Parkinson’s disease and Lewy body dementia, was discovered last year in people of African ancestry by researchers at NIH’s Center for Alzheimer's and Related Dementias (CARD). It appears to suppress the gene’s ability to make a functional version of an enzyme that helps brain cells recycle their proteins.

“This was an interesting finding, but it still didn’t answer how the variant was functioning to lower enzyme activity,” Pilar says.

From Friend to Foe: When the Immune System Turns on the Brain

IRP Research is Exploring the Role of Immune Cells in Dementia

Monday, November 4, 2024

If you visit a lab at NIH’s Center for Alzheimer’s and Related Dementias (CARD), you may find yourself surrounded by several robots hard at work nurturing the hundreds of sets of genetically modified stem cells that CARD scientists use to study the illnesses that give CARD its name. Many of these cells will be coaxed to mature into the neurons that power our movements, thoughts, and memories — but not all of them. Neurons have long received the lion share of dementia researchers’ attention, understandable seeing as the visible symptoms of Alzheimer’s disease are closely linked to a build-up of proteins — amyloid-beta and misfolded tau — that damage neurons. However, neurons aren’t the only brain cells involved in dementia.